Abstract
Despite significant progress in the treatment of acute myelogenous leukemia (AML), about 70% of patients who achieve complete remission with induction therapy relapse [1,2]. The prognosis of patients with AML who relapse is ominous. The remission rates are less than 30% in first salvage and less than 10% in subsequent salvages [3]. The incidence of long-term survivors in AML is less than 5% after relapse [3,4]. This stresses the need for new active agents and combination therapies to improve the response. The most effective therapy for AML includes arabinosylcytosine (ara-C), which must be anabolized to its active 5′-triphosphate (araCTP). A strong relationship has been demonstrated between clinical response and the pharmacokinetics and pharmacodynamics of ara-CTP in leukemia cells of patients receiving high-dose ara-C therapy for acute leukemia in relapse [5,6]. Similar trends were observed for patients with chronic myelogenous leukemia in blast crisis (CML-BC) after treatment with high-dose ara-C [7]. In patients with relapsed acute leukemia treated with high-dose ara-C, the half-life of ara-CTP elimination from cells, the trough concentration, and the total intracellular exposure to ara-CTP (the area under the accumulation and retention curve, AUC) were each correlated with the likelihood of achieving complete remission [5,6,8].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Keating MJ, McCredie KB, Bodey G P, Smith TL, Gehan E, Freireich EJ (1982) Improved prospects for long-term survival in adults with acute myelogenous leukemia. JAMA 248: 2481–2486
Freireich EJ (1987) Arabinosylcytosine: A 20-year update. J Clin Oncol 5: 523–524
Keating MJ, Kantarjian H, Smith TL, Estey E, Walters R, Andersson B, Beran M, McCredie KB, Freireich EJ (1989) Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 7: 1071–1080
Smits P, Schoots L, de Pauw BE, de Witte T, Holdrinet RSG, Janssen JTP, Haanen C (1987) Prognostic factors in adult patients with acute leukemia at first relapse. Cancer 59: 1631–1634
Plunkett W, Iacoboni S, Estey E, Danhauser L, Liliemark JO, Keating MJ (1985) Pharmaco logically directed ara-C therapy for refractory leukemia. Semin Oncol 12 (suppl 3): 20–30
Kantarjian HM, Estey EH, Plunkett W, Keating MJ, Walters RS, Iacoboni S, McCredie KB, Freireich EJ (1986) Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am J Med 81: 387–394
Iacoboni SJ, Plunkett W, Kantarjian HM, Estey E, Keating MJ, McCredie KB, Freireich EJ (1986) High-dose cytosine arabinoside: Treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis. J Clin Oncol 4: 1079–1088
Estey E, Plunkett W, Dixon DO, Keating MJ, McCredie KB, Freireich EJ (1987) Variables predicting response to high dose cytosine arabinoside therapy with refractory acute leukemia. Leukemia 1: 580–583
Blumenreich MS, Chou T-C, Andreeff M, Vale K, Clarkson BD, Young CW (1984) Thymidine as a kinetic and biochemical modulator of I-β-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia. Cancer Res 44: 825–830
Zittoun R, Zittoun J, Marquet J, Rustum Y, Creaven P (1985) Modulation of I-β-D-arabinofuranosylcytosine metabolism by thymidine in human acute leukemia. Cancer Res 45: 5186–5192
Schilsky RL, Williams SF, Ultmann JE, Watson S (1987) Sequential hydroxyurea-cytarabine chemotherapy for refractory non-Hodgkin’s lymphoma. J Clin Oncol 5: 419–425
Grant S, Bhalla K, Rauscher F, Cadman E (1983) Potentiation of I-β-D-arabinofuranosy1cytosine metabolism and cytotoxicity by 2,3-dihydro-1Himidazolo[I,2-b] pyrazole in the human promyelocytic leukemic cell, HL-60. Cancer Res 43: 5093–5100
Tseng W-C, Derse D, Cheng Y-C, Brockman RW, Bennett LL Jr (1982) In vitro biological activity of 9-β-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol Pharmacol 21: 474–477
White EL, Shaddix SD, Brockman RW, Bennett LL Jr (1982) Comparison of the action of 9-β-D-arabinofuranosyl-2-fluoroadenine on target enzymes from mouse tumor cells. Cancer Res 42: 2260–2264
Gandhi V, Plunkett W (1988) Modulation of arabinosylnucleoside metabolism by arabinosylnuc1eotides in human leukemia cells. Cancer Res 48: 329–334
Gandhi V, Nowak B, Keating MJ, Plunkett W (1989) Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy. Blood 74: 2070–2075
Kemena A, Keating MJ, Plunkett W (1991) Plasma and cellular bioavailability of oral fludarabine. Blood 78: 52a
Gandhi V, Kemena A, Keating MJ, Plunkett W (1992) Fludarabine infusion potentiates arabinosy1cytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res 52: 897–903
Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H, Keating MJ (1987) Saturation of I-β-D-arabinosylcytosine 5′ –triphosphate accumulation in leukemia cells during highdose I-β-D-arabinosylcytosine therapy. Cancer Res 47: 3005–3011
Plunkett W, Liliemark JO, Estey E, Keating MJ (1987) Saturation of ara-CTP accumulation during high-dose ara-C therapy: Pharmacologic rationale for intermediate-dose ara-C. Sem Oncol 14: (suppl. 1): 159–166
Estey EH, Plunkett W, Kantarjian H, Rios MB, Keating MJ (1993) Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): Confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C. Leukemia lymphoma 10 (suppl): 115–121
Hiddemann W (1991) Cytosine arabinoside in the treatment of acute myeloid leukemia: The role and place of high-dose regimens. Annals Hematol 62: 119–128
Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B, Velasquez W, Plunkett W, Freireich F, McCredie KB (1989) Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 74: 19–25
Keating MJ, Kantarjian H, O-Brien, Koller C, Talpaz M, Schachner J, Childs CC, Freireich EJ, McCredie KB (1991) Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 9: 44–49
Chun HG, Leyland-Jones BR, Caryk SM (1986) Central nervous system toxicity of fludarabine phosphate. Cancer treat Rept 70: 1225–1228
Danhauser L, Plunkett W, Keating MJ, Cabanillas F (1986) 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. Cancer Chern other Pharmacol 18: 145–152
Plunkett W, Nowak B, Keating MJ (1987) Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy. Cancer Treat Rept 71: 479–483
Gandhi V, Estey E, Keating MJ, Plunkett W (1993) Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 11: 116–124
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Gandhi, V., Keating, M.J., Estey, E., Plunkett, W. (1994). Modulation of Ara-C Metabolism by Fludarabine: Therapy for Acute Myelogenous Leukemia. In: Büchner, T., Hiddemann, W., Wörmann, B., Schellong, G., Ritter, J. (eds) Acute Leukemias IV. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 36. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78350-0_24
Download citation
DOI: https://doi.org/10.1007/978-3-642-78350-0_24
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-78352-4
Online ISBN: 978-3-642-78350-0
eBook Packages: Springer Book Archive